论文部分内容阅读
目的 评价前列腺移行带特异抗原密度 (PSAT)检测前列腺癌 (PCa)的临床价值。 方法 用酶免法测定 30例PCa及 88例良性前列腺增生症 (BPH)患者血清PSA水平 ,用经直肠前列腺B超测定患者总前列腺体积及移行带体积 ,并计算PSA密度 (PSAD)及PSAT值。 结果 PSA在 4～ 10ng/ml时 ,PCa和BPH患者PSAD值分别为 0 .2 6± 0 .11、0 .13± 0 .0 6 ,两组间相比差别具有显著性意义 (P <0 .0 1) ;PSAT值则分别为 1.0 4± 0 .70、0 .2 1± 0 .13 ,两组间相比差别具有显著性意义 (P <0 .0 1)。若选择PSAD =0 .15作为判断患者是否需穿刺活检的标准 ,将有 2 7%的PCa漏诊 ,而若选择PSAT =0 .35作为判断患者是否需穿刺活检的标准 ,只有 9%的PCa漏诊 (P <0 .0 1)。 结论 PSAT是一种新的有效的检测PCa的方法 ,PSA在 4～ 10ng/ml范围时 ,用PSAT检测PCa较用PSAD更精确。
Objective To evaluate the clinical value of prostatic adenocarcinoma (PSAT) in detecting prostate cancer (PCa). Methods Serum PSA levels were measured in 30 patients with PCa and 88 with benign prostatic hyperplasia (BPH) by enzyme immunoassay. The total prostatic volume and transition zone volume were measured with transrectal B-ultrasound and the PSAD and PSAT values were calculated . Results PSAD values of PCa and BPH patients were respectively 0.26 ± 0.11 and 0.13 ± 0.60 with a PSA of 4 to 10 ng / ml, with significant difference between the two groups (P <0 .0 1). The PSAT values were 1.04 ± 0.70,0.21 ± 0.13, respectively. There was significant difference between the two groups (P <0.01). If PSAD = 0.15 is selected as the criterion for determining whether a patient is biopsy-free, 27% of PCa will be missed, and if PSAT = 0.35 is used as the criterion for determining whether a patient is biopsy-free, only 9% (P <0. 01). Conclusions PSAT is a new and effective method to detect PCa. When PSA is in the range of 4 ~ 10ng / ml, the detection of PCa by PSAT is more accurate than PSAD.